Grace Therapeutics, Inc. (GRCE)

NASDAQ

$2.01

$-0.07

(-3.37%)

Pre-Market

Grace Therapeutics, Inc. (GRCE) Live Price Chart

Last updated: ⁦2026-10-13 10:24:40⁩. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.

Summary

Grace Therapeutics, Inc. (GRCE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.01, with a market capitalisation of $43.75M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.79 to $5.18. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$43.75M
Open	$2.02
Day's High	$5.18
Day's Low	$1.75
Previous Close	$2.08
Volume	39.76K
Average Volume	167.55K
P/E Ratio	--
52-Week High	$5.18
52-Week Low	$1.79
Dividend Yield	--
Earnings Date	--

Grace Therapeutics, Inc. (GRCE) Pre-Market Stock Price

Grace Therapeutics, Inc. (GRCE) is trading at $2.08 in pre-market trading as of 2026-10-12 23:31:00, unchanged from the previous close of $2.08

Pre-market trading shows how investors are pricing GRCE before the regular session opens. The current pre-market price is near the previous close, indicating neutral early trading sentiment.

Grace Therapeutics, Inc. (GRCE) 7-Day Stock Price Change

Over the past seven days, Grace Therapeutics, Inc. (GRCE) moved from $2.07 to $2.01, representing a decline of 2.90% ($0.06).

The stock traded between $1.98 and $2.14 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.

The average daily volume was 74.37 thousand shares, down versus the previous seven-day period, indicating lower trading activity.

GRCE 52-Week Price Position

Position in Range: 6.5%

52W Low$1.79

52W High$5.18

GRCE is currently trading at $2.01, placing it 6.5% of the way from its 52-week low of $1.79 to its 52-week high of $5.18. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Grace Therapeutics, Inc. (GRCE)?

Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.

Grace Therapeutics, Inc. Information

Industry	PHARMACEUTICAL PREPARATIONS
Employees	5
Exchange	NASDAQ
Company Website	https://www.gracetx.com

How to Buy Grace Therapeutics, Inc. (GRCE) Stock on MEXC

Eligible investors can buy real shares of Grace Therapeutics, Inc. (GRCE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licenced broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for GRCE and Place Your Order

Open the RealStocks trading page and search for GRCE. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Grace Therapeutics, Inc. (GRCE) stock price today?

Grace Therapeutics, Inc. (GRCE) is currently trading at $ 2.01, down 3.37% ($0.07) from the previous close of $ 2.08. Intraday prices update in real time during regular trading hours.

2.Is GRCE stock going up or down today?

As of 2026-10-12 23:31:00, GRCE is trading at $ 2.01, down 3.37% ($0.07) from its previous close of $ 2.08. The stock has traded between $ 1.75 and $ 5.18 during today’s regular session. Past price movements do not guarantee future results.

3.What is GRCE pre-market price?

As of 2026-10-12 23:31:00, GRCE is trading at $ 2.08 in pre-market trading, unchanged from the previous close of $ 2.08. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is GRCE after-hours price?

As of 2026-10-12 23:31:00, GRCE is trading at $ 1.96 in after-hours trading, down 5.72% ($0.12) from the regular-session close of $ 2.08. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is GRCE stock trading now?

GRCE trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does GRCE sit relative to its 52-week high and low?

Over the past 52 weeks, GRCE has traded between a low of $ 1.79 and a high of $ 5.18. At $ 2.01, the stock is positioned 6.5% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Grace Therapeutics, Inc. in?

Grace Therapeutics, Inc. (GRCE) operates in the PHARMACEUTICAL PREPARATIONS sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Grace Therapeutics, Inc.'s market capitalisation and where is it listed?

Grace Therapeutics, Inc. is listed on the NASDAQ exchange with a market capitalisation of $ 43.75M. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is GRCE valued in terms of P/E ratio and EPS?

GRCE trades at a P/E ratio of --, based on trailing-twelve-month EPS of $ -0.96. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Grace Therapeutics, Inc. pay a dividend?

Grace Therapeutics, Inc. pays an indicated annual cash dividend of $ 0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.